Previous genomic and transcriptomic studies have revealed that critical gene mutations or aberrant signaling pathways driving the pathogenesis of PDAC, such as KRAS (over 90%), TP53, SMAD4 and CDKN2A (over 50%) (Australian Pancreatic Cancer Genome Initiative et al., 2012; Witkiewicz et al., 2015). This evidence concerns the gene KRAS and familial pancreatic carcinoma.